Molecular Partners reports Q3 2026 results, shifts focus to radiopharmaceuticals

Molecular Partners AG announced its unaudited Q3 2026 financial results and a strategic transformation to focus exclusively on radiopharmaceutical development. The company is streamlining resources, with full implementation expected by Q2 2027 and cost reductions effective in H2 2027.

Detected & updated continuously · Source: Nebula